Who are Dantrolene sodium for injectable suspension's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ryanodex, Ryanodex and Standard of Care.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dantrolene-sodium-for-injectable-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dantrolene sodium for injectable suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dantrolene sodium for injectable suspension (Dantrolene sodium for injectable suspension) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting muscle relaxant. Area: Musculoskeletal.

phase 2 Direct-acting muscle relaxant Ryanodine receptor Musculoskeletal Small molecule Live · refreshed every 30 min

Target snapshot

Dantrolene sodium for injectable suspension (Dantrolene sodium for injectable suspension) — Eagle Pharmaceuticals, Inc.. Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dantrolene sodium for injectable suspension TARGET	Dantrolene sodium for injectable suspension	Eagle Pharmaceuticals, Inc.	phase 2	Direct-acting muscle relaxant	Ryanodine receptor
Ryanodex	DANTROLENE	Ph Health	marketed	Skeletal Muscle Relaxant	Ryanodine receptor 1	1974-01-01
Ryanodex and Standard of Care	Ryanodex and Standard of Care	Eagle Pharmaceuticals, Inc.	phase 3	Ryanodine receptor antagonist	Ryanodine receptor (RyR1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting muscle relaxant class)

Eagle Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dantrolene sodium for injectable suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/dantrolene-sodium-for-injectable-suspension. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab